Testing a new drug for safety in healthy people and those with nerve pain after shingles
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Pain clinical trials.
This study tests an experimental drug, iN1011-N17, to see how safe it is and how the body processes it. It involves healthy volunteers and people with postherpetic neuralgia (nerve pain after shingles). This may help find better treatments for this type of chronic pain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Healthy volunteers must be 18 to 55 years old; people with nerve pain after shingles must be 50 to 75.
- You need to have a body mass index between 18 and 32 (healthy) or up to 40 (nerve pain group), and weigh at least 99 pounds.
- You must be in generally good health with no major medical conditions or history of cancer, liver, kidney, or nerve disease.
- You must agree to use effective birth control during the study and for at least 30 days (women) or 90 days (men) after.
- You cannot have used any other study drugs or certain medications recently, and you must be willing to stop all pain medicines for a while (nerve pain group).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage study testing a new investigational drug called IG001119 in people who are in good health. Researchers will give increasing doses to small groups to learn how the drug is processed by the body and to check for any side effects.
This trial tests an extended-release version of pregabalin (a pain medication) for people with long-term nerve pain caused by diabetes or shingles. It aims to see if this once-daily pill can reduce pain with fewer side effects.
This trial tests a new pain medication called tulodesvenlafaxine for people with shingles-related pain. It may help if you have moderate to severe pain that started within the last 90 days.
This trial tests a new tablet called HL-1186 for treating post-herpetic neuralgia (long-lasting pain after shingles). It compares the new drug to pregabalin, a standard treatment, to see if it's safer and more effective.
This study tests whether a spray medication called APC101 can safely reduce pain from shingles that lasts longer than 3 months. The pain usually starts after a shingles rash heals, and this trial investigates whether applying the spray to affected skin areas twice daily helps.
This study tests a new drug (HL-1186) for diabetic nerve pain. It aims to see if it reduces pain safely in people with type 1 or type 2 diabetes who have had nerve pain for at least 6 months.
Hear when a new Post Herpetic Neuralgia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.